Nippon Shinyaku and Taiho strike itching product alliance
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku has licensed an early-stage pipeline product for serious itching to Taihofor co-development and co-marketing in Japan. The compound, NS-141, is still at the preclinical stage and represents a new approach to serious itching related to disorders such as atopic dermatitis, Nippon Shinyaku said. Taiho will make undisclosed up front, milestone and royalty payments as part of the deal and will join the development programme from Phase I.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.